Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that two late-stage studies for its Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib, used in the treatment of chronic spontaneous urticaria (CSU), have successfully met all primary and secondary endpoints at the 12-week mark of a 52-week trial. After three months of treatment with the oral drug, a significantly higher proportion of patients experienced well-controlled disease, along with a complete absence of itch and hives compared to those on a placebo.
Safety Profile and Upcoming Filings
The overall adverse event rate in the remibrutinib group was 64.4%, which is comparable to the 64.7% observed in the control group. Novartis anticipates compiling sufficient clinical data to support global filings for remibrutinib in the coming year.- Flcube.com
